FindTrial
Sign In

A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined MenC-Hib Conjugate Vaccine, OR Separate Administration of Chiron Hib Conjugate Vaccine (VaxemHib) and Chiron MenC Conjugate Vaccine (Menjugate), OR One Dose of Menjugate, OR One Dose of VaxemHib

A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined MenC-Hib Conjugate Vaccine, OR Separate Administration of Chiron Hib Conjugate Vaccine (VaxemHib) and Chiron MenC Conjugate Vaccine (Menjugate), OR One Dose of Menjugate, OR One Dose of VaxemHib

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-000767-10-IT
Enrollment
Unknown
Registered
2005-06-28
Start date
2004-06-29
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active immnunisation for the prevention of invasive disease caused by N. Meningitidis serogroup C and H. influenzae type b MedDRA version: 6.1 Level: PT Classification code 10027249

Interventions

Product Name: Combined MenC-Hib conjugate vaccine Product Code: V82 Pharmaceutical Form: Powder and solvent for suspension for injection Current Sponsor code: V82 Concentration unit: µg microgram(s) C

Sponsors

CHIRON
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026